InSingulo Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 1

InSingulo General Information

Description

Developer of a drug technology designed to overcome the challenges of label-free biosensing in drug development and research. The company develops next-generation label-free methods that allow inhibition to reveal detailed kinetic information, enabling businesses to overcome the challenges of biophysics in drug discovery using single-molecule microscopy.

Contact Information

Website
www.insingulo.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • Box 161, Stenungsund
  • Pepparedsleden 1
  • 444 22 Molndal
  • Sweden
+46
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Box 161, Stenungsund
  • Pepparedsleden 1
  • 444 22 Molndal
  • Sweden
+46

InSingulo Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

InSingulo Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private 03-Aug-2026 Completed Generating Revenue
4. Seed Round 20-Feb-2024 Completed Generating Revenue
3. Seed Round 22-Nov-2022 Completed Generating Revenue
2. Seed Round 31-Dec-2020 $550K $550K Completed Generating Revenue
1. Grant 01-Sep-2019 $207K Completed Generating Revenue
To view InSingulo’s complete valuation and funding history, request access »

InSingulo Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
Ordinary 23,000 $19.11 $19.11 1x $19.11 10.83%
To view InSingulo’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

InSingulo Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a drug technology designed to overcome the challenges of label-free biosensing in drug development and rese
Discovery Tools (Healthcare)
Molndal, Sweden
12 As of 2024

Munich, Germany
 

Goettingen, Germany
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

InSingulo Competitors (2)

One of InSingulo’s 2 competitors is NanoTemper Technologies, a Corporation company based in Munich, Germany.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NanoTemper Technologies Corporation Munich, Germany
Sartorius Corporation Goettingen, Germany
You’re viewing 2 of 2 competitors. Get the full list »

InSingulo Patents

  • 14

    Total Documents Applications and Grants

  • Total Patents Families

  • 10

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

InSingulo Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026122010-A1 System & method for generating an evanescent field for total internal reflection fluorescence (tirf) microscopy Pending 04-Dec-2024
EP-3830577-A1 A method for determining the interaction between a ligand and a receptor Active 03-Aug-2018
EP-3830577-B1 A method for determining the interaction between a ligand and a receptor Active 03-Aug-2018
EP-3830577-C0 A method for determining the interaction between a ligand and a receptor Active 03-Aug-2018
US-20210181193-A1 A method for determining the interaction between a ligand and a receptor Active 03-Aug-2018 G01N33/54373
To view InSingulo’s complete patent history, request access »

InSingulo Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

InSingulo Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Vinnova Government
To view InSingulo’s complete investors history, request access »

Ready to get started?

Request a free trial

InSingulo FAQs

  • When was InSingulo founded?

    InSingulo was founded in 2017.

  • Where is InSingulo headquartered?

    InSingulo is headquartered in Molndal, Sweden.

  • What is the size of InSingulo?

    InSingulo has 12 total employees.

  • What industry is InSingulo in?

    InSingulo’s primary industry is Discovery Tools (Healthcare).

  • Is InSingulo a private or public company?

    InSingulo is a Private company.

  • What is InSingulo’s current revenue?

    The current revenue for InSingulo is .

  • How much funding has InSingulo raised over time?

    InSingulo has raised $5.92M.

  • Who are InSingulo’s investors?

    Vinnova has invested in InSingulo.

  • Who are InSingulo’s competitors?

    NanoTemper Technologies and Sartorius are competitors of InSingulo.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process